Cabazitaxel or mitoxantrone with prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel: Estimating mean overall survival (OS) for health economic analyses from a phase III trial (TROPIC).

Authors

Stephane Oudard

Medical Oncology Department, Georges Pompidou European Hospital

Stephane Oudard , A. Sartor

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2018 Genitourinary Cancers Symposium

bookmark_border

Cabozantinib for metastatic castration-resistant prostate cancer (mCRPC) following docetaxel: Combined analysis of two phase III trials.

First Author: Gregory Russell Pond

insert_chart_outlined

Poster

2016 ASCO Annual Meeting

bookmark_border

Validation of the association of RECIST 1.0 changes with survival in men with metastatic castration resistant prostate cancer (mCRPC) treated on SWOG Study S0421.

First Author: Gregory Russell Pond

insert_chart_outlined

Poster

2015 Genitourinary Cancers Symposium

bookmark_border

Final analysis of COMET-2: Cabozantinib (Cabo) versus mitoxantrone/prednisone (MP) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) with moderate to severe pain who were previously treated with docetaxel (D) and abiraterone (A) and/or enzalutamide (E)

First Author: Ethan M. Basch

insert_chart_outlined

Poster

2014 Genitourinary Cancers Symposium

bookmark_border

Regional analysis of a cohort compassionate-use program (CUP) and early access program (EAP) with cabazitaxel (Cbz) plus prednisone (P; Cbz + P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel (D).

First Author: Zafar Malik